. S  T  A  T  5  c  a  n   h  a  v  e  a  r  e  g  u  l  a  t  o  r  y  e  f  f  e  c  t  o  n  c  e  l  l  s  u  r  v  i  v  a  l  ,  d  a  m  p  e  n  i  n  g  t  h  e  p  r  o  -s  u  r  v  i  v  a  l  e  f  f  e  c  t  s  o  f  o  t  h  e  r   p  S  T  A  T  s  .   6   4   T  o  t  e  s  t  o  u  r  h  y  p  o  t  h  e  s  i  s  ,  w  e  s  t  u  d  i  e  d  2  4  p  a  i  r  s  o  f  s  a  m  p  l  e  s  ,  f  r  o  m  d  i  a  g  n  o  s  i  s  a  n  d  r  e  l  a  p  s  e  .   C  r  y  o  p  r  e  s  e  r  v  e  d  b  o  n  e  m  a  r  r  o  w  c  e  l  l  s  w  e  r  e  o  b  t  a  i  n  e  d  f  r  o  m  t  h  e  C  h  i  l  d  r  e  n  '  s  O  n  c  o Table 1 ).
Control Cells
The human AML cell line Kasumi-1 was used as the positive control for ligand stimulation. 1
Kasumi-1 cells were obtained from ATCC, and grown in RPMI (ATCC) supplemented with 10% FBS and 100 units/mL penicillin and 100 g/mL streptomycin. Kasumi-1 cells were grown in a humidified 37 o C incubator with 5% CO2. Kasumi-1 cells were processed simultaneously along with every patient sample in 4 aliquots, including isotype control, unstimulated, 100 ng/mL G-CSF, and 50/100 ng/mL IL-6/soluble IL-6 Receptor alpha (sIL-6R. Responses for control cells were consistent across experiments and with previously published data. 1, 2
Flow Cytometry
Cells were aliquoted into 9 wells at 1-2x10 5 cells/well. Five wells were left unstimulated for the measurement of isotype controls, constitutive pSTATs, receptor expression, total STAT3, and pY418-SRC. Two wells were stimulated with 10 or 100 ng/mL G-CSF (Filgrastim, Amgen), and two wells were stimulated with 5 or 50 ng/mL IL-6 (BD Pharmingen) + 10 or 100 ng/mL sIL-6R (R&D Biosystems), respectively. Incubation, fixing, and permeabilization were carried out as previously described. 1, 2 Cells were washed in flow buffer (phosphate buffered saline with 900 mg/L sodium azide and 2g/L bovine serum albumin) and stained for 30 minutes at room temperature with the appropriate fluorochrome-conjugated antibodies. After staining, cells were washed and analyzed on an LSRII (BD Biosciences). Data were collected using Diva (BD Biosciences) and subsequently analyzed using FCS Express4 (DeNovo). For all samples, Side Scatter (SSC) vs. CD45 was used to gate on the blast population and exclude residual lymphocytes or monocytes (Supplementary Figure 1A) . Constitutive pY-STAT3, pS-STAT3, pY-STAT5, and phosphotyrosine SRC (pY418-SRC) were measured in unstimulated AML cells, as well as total STAT3, the G-CSF receptor (G-CSFR), and the interleukin-6 receptor transmembrane subunit (gp130). After gating on the blast population, the percentage of positive events was measured for each antigen, using gates set to include <1% of events in the isotype control condition (Supplementary Figure 1B) . The differences between relapse and diagnosis were calculated by subtracting the percent positive at diagnosis from the percent positive at relapse.
Flow Cytometry Antibodies
Intracellular flow cytometry antibodies were purchased from BD Biosciences, including pY- 
Statistical Analysis
The significance of observed differences between matched pairs was analyzed by the Toxic deaths (deaths not primarily attributable to the underlying disease) are frequent in patients undergoing hematopoietic stem cell transplant, and we identified 4 toxic deaths in our cohort of 24 patients (two due to infection/multiorgan failure and two due to cardiomyopathy). As deaths due to toxicity do not reflect the disease status at the time of death, these patients were censored when comparing for differences in survival between groups. Estimates of OS are reported with corresponding Greenwood standard errors.
Groups were compared for significant differences by the log-rank test.
AAML0531 Treatment
Treatment on AAML051 consisted of up to 5 blocks of standard cytotoxic chemotherapy with randomization to ± gemtuzumab ozogamicin (GO). 3 Patients were also eligible for HSCT in first complete remission (CR1) based on their risk group. Patients who were eligible for HSCT in CR1 went to transplant after completing 3 of the 5 planned blocks of standard cytotoxic chemotherapy ± GO. Intrathecal cytarabine was administered on day 1 of every cycle (more frequently if patient was found to be CNS positive at diagnosis). Cycles lasted a minimum of 28 days before proceeding to the next cycle. The chemotherapy administered during each cycle is as follows:
Supplemental 
